BerGenBio ASA 7BG.F Stock
BerGenBio ASA Price Chart
BerGenBio ASA 7BG.F Financial and Trading Overview
| BerGenBio ASA stock price | 0.01 EUR |
| Previous Close | 0.02 EUR |
| Open | 0.02 EUR |
| Bid | 0.01 EUR x 11000000 |
| Ask | 0.04 EUR x 3793200 |
| Day's Range | 0.02 - 0.02 EUR |
| 52 Week Range | 0.0001 - 1.4 EUR |
| Volume | 1.9K EUR |
| Avg. Volume | 1.96K EUR |
| Market Cap | 2.7M EUR |
| Beta (5Y Monthly) | 1.884291 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.05 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
7BG.F Valuation Measures
| Enterprise Value | -149047376 EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 6.9284344 |
| Price/Book (mrq) | 0.016232464 |
| Enterprise Value/Revenue | -383.155 |
| Enterprise Value/EBITDA | 0.488 |
Trading Information
BerGenBio ASA Stock Price History
| Beta (5Y Monthly) | 1.884291 |
| 52-Week Change | -98.42% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.4 EUR |
| 52 Week Low | 0.0001 EUR |
| 50-Day Moving Average | 0.2 EUR |
| 200-Day Moving Average | 0.55 EUR |
7BG.F Share Statistics
| Avg. Volume (3 month) | 1.96K EUR |
| Avg. Daily Volume (10-Days) | 4K EUR |
| Shares Outstanding | 102.69M |
| Float | 51.88M |
| Short Ratio | N/A |
| % Held by Insiders | 34.58% |
| % Held by Institutions | 18.92% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -78569.14% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -61.92% |
| Return on Equity (ttm) | -127.76% |
Income Statement
| Revenue (ttm) | 389K EUR |
| Revenue Per Share (ttm) | 0.004 EUR |
| Quarterly Revenue Growth (yoy) | -49.70% |
| Gross Profit (ttm) | 389K EUR |
| EBITDA | -305553984 EUR |
| Net Income Avi to Common (ttm) | -302121984 EUR |
| Diluted EPS (ttm) | -0.24 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 150.8M EUR |
| Total Cash Per Share (mrq) | 1.7 EUR |
| Total Debt (mrq) | 275K EUR |
| Total Debt/Equity (mrq) | 0.31 EUR |
| Current Ratio (mrq) | 2.139 |
| Book Value Per Share (mrq) | 0.998 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -288231008 EUR |
| Levered Free Cash Flow (ttm) | -176587872 EUR |
Profile of BerGenBio ASA
| Country | Germany |
| State | N/A |
| City | Bergen |
| Address | Møllendalsbakken 9 |
| ZIP | 5009 |
| Phone | 47 55 96 11 59 |
| Website | https://www.bergenbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 29 |
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Q&A For BerGenBio ASA Stock
What is a current 7BG.F stock price?
BerGenBio ASA 7BG.F stock price today per share is 0.01 EUR.
How to purchase BerGenBio ASA stock?
You can buy 7BG.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BerGenBio ASA?
The stock symbol or ticker of BerGenBio ASA is 7BG.F.
Which industry does the BerGenBio ASA company belong to?
The BerGenBio ASA industry is Biotechnology.
How many shares does BerGenBio ASA have in circulation?
The max supply of BerGenBio ASA shares is 2.88B.
What is BerGenBio ASA Price to Earnings Ratio (PE Ratio)?
BerGenBio ASA PE Ratio is now.
What was BerGenBio ASA earnings per share over the trailing 12 months (TTM)?
BerGenBio ASA EPS is -0.05 EUR over the trailing 12 months.
Which sector does the BerGenBio ASA company belong to?
The BerGenBio ASA sector is Healthcare.